Critical Review: uniQure (NASDAQ:QURE) vs. Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ:EXEL – Get Free Report) and uniQure (NASDAQ:QURE – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Volatility & Risk

Exelixis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, uniQure has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Profitability

This table compares Exelixis and uniQure’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exelixis 35.45% 45.54% 33.90%
uniQure -1,154.84% -96.34% -26.40%

Insider and Institutional Ownership

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Exelixis and uniQure, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis 1 10 6 1 2.39
uniQure 1 3 11 1 2.75

Exelixis presently has a consensus price target of $58.85, suggesting a potential downside of 15.02%. uniQure has a consensus price target of $56.83, suggesting a potential upside of 139.28%. Given uniQure’s stronger consensus rating and higher possible upside, analysts plainly believe uniQure is more favorable than Exelixis.

Earnings and Valuation

This table compares Exelixis and uniQure”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Exelixis $2.32 billion 7.28 $782.57 million $3.34 20.73
uniQure $20.17 million 82.61 -$198.97 million ($3.51) -6.77

Exelixis has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Summary

Exelixis beats uniQure on 8 of the 14 factors compared between the two stocks.

About Exelixis

(Get Free Report)

Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.